Scholar Rock's Manufacturing Scare Was Months Ago. The 2.7x Peak Revenue Math Is What's Left.

Scholar Rock ($SRRK) still carries the market's memory of a November 2025 Complete Response Letter like it was an efficacy failure. It wasn't. The FDA flagged manufacturing observations at a fill-finish contractor, not the drug itself. The BLA was resubmitted in March, accepted in May, and is now progressing through review with two independent manufacturing paths. The PDUFA action date — September 30 — is roughly eight weeks away.

At roughly $5.7 billion in market cap and about $5.4 billion in enterprise value (after $492 million in cash and $270 million in debt), the stock trades at approximately 2.7 times management's own $2 billion peak revenue guidance. That's the number that matters. The CRL noise was a chapter. The valuation math is the thesis.

1. The CRL was about factories, not the drug.

The FDA's September 2025 Complete Response Letter cited observations from a routine inspection of Catalent Indiana LLC, Scholar Rock's fill-finish facility. The letter contained no efficacy or safety concerns. Novo Nordisk, which owns Catalent, submitted a remediation plan in August 2025. By early 2026, the FDA had agreed with the corrective actions. No additional changes were requested after a follow-up site visit.

The clinical data isn't the question. Apitegromab — a monoclonal antibody that blocks myostatin, a protein that limits muscle growth — is the first muscle-targeted therapy to show statistically significant motor function improvement in a Phase 3 SMA trial (SAPPHIRE). Patients on apitegromab gained 1.8 points on the HFMSE scale versus placebo (p = 0.019) over 52 weeks, with 30.4% showing a clinically meaningful 3-plus point gain versus 12.5% on placebo. The drug worked. The FDA knew it. The manufacturing issue was procedural, not foundational.

2. Two fill-finish facilities mean the supply chain isn't a single point of failure.

Most pre-launch biotecks go to the FDA with one manufacturing site. Scholar Rock submitted its resubmitted BLA with a second U.S.-based fill-finish facility already in the data package. The second site was added after a Type C meeting on March 3, 2026, and commercial capacity has been reserved starting Q1 2026. Ample supply from the second facility is available for launch.

This isn't window dressing. A single-site manufacturer is the classic regulatory tail risk — and it's exactly what nearly derailed the first BLA submission. Dual facilities make that risk structural history.

3. Management raised peak revenue guidance from $1 billion to over $2 billion.

At J.P. Morgan Healthcare Conference in January 2026, Scholar Rock's CEO updated the global peak revenue estimate for apitegromab. The raise signals management confidence that the drug can capture significant share in an addressable SMA market of roughly $4.5 billion. Spinraza, the incumbent leader, generated approximately $1.6 billion in recent revenue; Roche's Evrysdi has reshaped the treatment paradigm with oral administration at a $2.1 million list price.

Apitegromab targets non-ambulatory Type 2/3 SMA patients already on SMN-targeted therapies. It's positioned as complementary to existing treatments, not a replacement — a muscle-growth adjunct layered on top of the SMN platform drugs. That add-on positioning avoids a zero-sum fight with incumbents and opens a broader total addressable market.

4. The balance sheet is fortified, not fraying.

As of June 30, Q2 2026, Scholar Rock held $492 million in cash and marketable securities. That's up from roughly $365 million at the end of 2025, boosted by a $200 million draw on a Blue Owl term loan and $63 million from an at-the-market equity offering during the quarter. Q2 net loss was $110 million, roughly in line with the $110 million reported a year earlier.

The company is burning cash to fund R&D ($58 million in Q2) and build the commercial team ahead of a potential September launch. That's the expected pattern for a biotech crossing the approval threshold. The capital raise removes the dilution overhang that typically worries investors in pre-revenue companies approaching binary events.

5. The binary date is close.

September 30 is the PDUFA action date. If approved, Scholar Rock can launch immediately — the commercial team is already active in disease education and prescriber engagement. The EMA's review of the Marketing Authorisation Application is also progressing, with a decision anticipated mid-2026, which means European launch could follow shortly after U.S. approval.

The pipeline extends beyond SMA too. The Phase 2 FORGE trial in facioscapulohumeral muscular dystrophy (FSHD) has begun enrollment. SRK-439, an oral/subcutaneous myostatin inhibitor targeting the roughly $90 billion obesity market, is in Phase 1 with topline data expected late 2026. The subcutaneous apitegromab formulation showed favorable bioavailability comparable to IV in Phase 1.

What would break the thesis

The FDA could issue another CRL if manufacturing deficiencies resurface or if additional clinical data is requested. The approval isn't guaranteed, and binary events always carry the risk of a rejection. If apitegromab fails to launch in 2026, the market cap would likely re-rate sharply lower.

The closer

At roughly 2.7 times $2 billion in peak revenue guidance, Scholar Rock's enterprise value doesn't reflect the drug's approval probability, the dual-facility supply chain, the complementary positioning in SMA, or the pipeline options in FSHD and obesity. AInvest's aggregate signal labels the stock a Buy, and the composite analysis rating leans bullish — but the math does the heavy lifting.

A false narrative is still hanging around the stock from the manufacturing CRL that was resolved months ago. The real variable is whether the FDA opens the door on September 30. If it does, 2.7x peak revenue is a deep discount for a drug targeting a $4.5 billion addressable market with a differentiated mechanism and a $2 billion revenue path already in management's own model.